Immunogenicity and safety of inactivated chromatographically purified Vero cell-derived Japanese encephalitis vaccine in Thai children.

Autor:	Chanthavanich P; a Department of Tropical Pediatrics , Faculty of Tropical Medicine, Mahidol University , Thailand., Limkittikul K; a Department of Tropical Pediatrics , Faculty of Tropical Medicine, Mahidol University , Thailand., Sirivichayakul C; a Department of Tropical Pediatrics , Faculty of Tropical Medicine, Mahidol University , Thailand., Chokejindachai W; a Department of Tropical Pediatrics , Faculty of Tropical Medicine, Mahidol University , Thailand., Hattasingh W; a Department of Tropical Pediatrics , Faculty of Tropical Medicine, Mahidol University , Thailand., Pengsaa K; a Department of Tropical Pediatrics , Faculty of Tropical Medicine, Mahidol University , Thailand., Surangsrirat S; b Nopparat Rajathanee Hospital, Ministry of Public Health , Thailand., Srisuwannaporn T; b Nopparat Rajathanee Hospital, Ministry of Public Health , Thailand., Kaewma B; b Nopparat Rajathanee Hospital, Ministry of Public Health , Thailand., Yoksan S; c Japanese Encephalitis/Dengue Virology Laboratory, Center for Vaccine Development , Institute of Molecular Biosciences, Mahidol University , Thailand., Jun G; d Liaoning Cheng Da Biotechnology Co., Ltd. , China., Zhumu B; d Liaoning Cheng Da Biotechnology Co., Ltd. , China.
Jazyk:	angličtina
Zdroj:	Human vaccines & immunotherapeutics [Hum Vaccin Immunother] 2018 Apr 03; Vol. 14 (4), pp. 900-905. Date of Electronic Publication: 2018 Jan 16.
DOI:	10.1080/21645515.2017.1414763
Abstrakt:	Inactivated mouse-brain-derived Japanese encephalitis vaccine has a worrisome safety profile and the live attenuated vaccine is unsuitable in immunodeficiency. This study aimed to evaluate the immunogenicity and safety of an inactivated chromatographically purified Vero-cell-derived JE vaccine (CVI-JE, Beijing P-3 strain) in children. 152 healthy Thai children, with an average (SD) age of 14.4 (3.8) months, received 3 doses of CVI-JE on days 0, 7-28, and one year. Homologous JE neutralizing antibody titers (NT) were measured. All subjects had seroprotection [geometric mean titer (GMT) 150] 28 days' post 2nd vaccination. The seroprotection rates at 1 year after primary series and and 1 month after the booster were 89.3% (GMT 49) and 100% (GMT 621), respectively. Local and systemic reactions-fever (17.6%), vomiting (8%), and poor appetite (5.3%)-were noted within 28 days' post-vaccination. All these symptoms were self-limited. Conclusions: CVI-JE is safe, immunogenic, and provided high NT.
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu